NEW YORK--(BUSINESS WIRE)--Sept. 18, 2006--Bioenvision, Inc. (NasdaqGM:BIVN) today announced it is expanding into Japan and Southeast Asia for the clinical and commercial development of Evoltra(R) (clofarabine) in this newly licensed territory. Bioenvision licensed these previously ungranted rights to manufacture, sell, market and distribute Evoltra in this region from Southern Research Institute of Birmingham, Alabama, the inventor of clofarabine.
